Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lisata Therapeutics, Inc. - Common Stock
(NQ:
LSTA
)
2.060
+0.050 (+2.49%)
Streaming Delayed Price
Updated: 3:37 PM EST, Dec 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Lisata Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Lisata Therapeutics (NASDAQ:LSTA) Reports Narrower-Than-Expected Q3 2025 Loss
↗
November 06, 2025
Lisata Therapeutics reported a narrower-than-expected Q3 2025 loss, advancing its lead candidate, certepetide, with a cash runway into 2027.
Via
Chartmill
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 04, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
July 21, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
Earnings Scheduled For November 12, 2024
↗
November 12, 2024
Via
Benzinga
Earnings Outlook For Lisata Therapeutics
↗
November 11, 2024
Via
Benzinga
Recap: Lisata Therapeutics Q4 Earnings
↗
February 29, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
↗
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Lisata Therapeutics's Earnings Outlook
↗
February 28, 2024
Via
Benzinga
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales
↗
January 22, 2025
Via
Benzinga
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earnings
↗
January 22, 2025
Via
Benzinga
US Stocks Higher; Netflix Profit Beats Estimates
↗
January 22, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
January 22, 2025
Via
Benzinga
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
↗
January 22, 2025
Via
Benzinga
Earnings Preview: Lisata Therapeutics
↗
November 01, 2023
Via
Benzinga
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024
↗
August 12, 2024
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
↗
July 18, 2024
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing...
Via
Benzinga
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
May 13, 2024
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Via
News Direct
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q1 2024
↗
May 09, 2024
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Earnings Scheduled For March 30, 2023
↗
March 30, 2023
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.
Via
Benzinga
Earnings Scheduled For August 14, 2023
↗
August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
December 23, 2022
OnFriday, 143 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
December 14, 2022
On Wednesday, 115 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
December 13, 2022
On Tuesday, 49 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
October 18, 2022
During Tuesday's session, 78 companies made new 52-week lows.
Via
Benzinga
121 Stocks That Hit Their 52-Week Low
↗
October 14, 2022
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.
Via
Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
↗
September 19, 2022
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Via
Benzinga
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today